SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-22-005464
Filing Date
2022-04-14
Accepted
2022-04-14 16:05:22
Documents
5
Period of Report
2022-05-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20220526xdef14a.htm DEF 14A 639392
2 GRAPHIC tmb-20220526xdef14a002.jpg GRAPHIC 4531
3 GRAPHIC tmb-20220526xdef14a001.jpg GRAPHIC 12602
4 GRAPHIC tmb-20220526xdef14a004.jpg GRAPHIC 169738
5 GRAPHIC tmb-20220526xdef14a005.jpg GRAPHIC 182497
  Complete submission text file 0001558370-22-005464.txt   1149650
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39746 | Film No.: 22827267
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences